Physician profile
John W Lamiot
NPI 1871636670
$746.33
in general payments reported to CMS, 2019-2025
12 companies · $299 in 2025
The $299 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $18.27 · 2021: $18.60 · 2024: $169 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $467.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Surgenex LLC | $280.82 | 2025 | Renograft, Surgraft, Ardeograft |
| Mimedx Group, INC. | $132.22 | 2024 | |
| Smith+Nephew, INC. | $62.04 | 2019-2024 | Grafix |
| Kerecis Limited | $54.48 | 2019 | |
| Paratek Pharmaceuticals, INC. | $49.12 | 2019 | |
| Stryker Corporation | $39.29 | 2019 | |
| Convatec INC. | $38.88 | 2019-2021 | |
| Solventum Corporation | $23.13 | 2024 | Activ.A.C. |
| Hartmann USA, INC. | $18.63 | 2025 | Zetuvit Plus 10x10 P10 |
| Medline Industries LP | $18.27 | 2020 | |
| Tactile Systems Technology INC | $18.22 | 2019 | |
| Merck Sharp & Dohme LLC | $11.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lamiot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.